Clincosm LogoSign in Get a demo

BPM: Mycoprotein and Pea Protein Blend and Muscle Protein Synthetic Response

Sponsor
University of Exeter (Other)
Overall Status
Recruiting
CT.gov ID
NCT04894747
Collaborator
Quorn (Industry)
36
Enrollment
1
Location
3
Arms
14
Anticipated Duration (Months)
2.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Dietary protein is vital for the preservation of health and optimal adaptation to training. Plant proteins are considered inferior to animal proteins with respect to their ability to stimulate an acute muscle building response and therefore support long-term muscle reconditioning. Pea protein is a highly commercially available plant proteins source (available as supplements, food ingredients etc.), yet there is no research investigating its ability to stimulate a muscle building response. The investigators aim to assess the effect of consuming pea protein on muscle protein synthesis rates and compare these results to mycoprotein, a source known to elicit a robust anabolic response.

Pea protein is lower in some of the essential amino acids, namely methionine, which could mean it is less effective compared with mycoprotein which has a more complete amino acid profile. So in addition to comparing pea with mycoprotein, the investigators also want to compare to a blend of pea and mycoprotein to see if replenishing the amino acid content in pea 'rescues' the anabolic response.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Bolus ingestion of protein
 N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
36 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Basic Science
Official Title:
Comparing Postprandial Muscle Protein Synthesis Rates Following the Consumption of Mycoprotein, Pea Protein and a Mycoprotein/Pea Protein Blend in Resistance Trained Individuals
Actual Study Start Date :
May 1, 2021
Anticipated Primary Completion Date :
Jul 1, 2022
Anticipated Study Completion Date :
Jul 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Mycoprotein

Bolus ingestion of mycoprotein providing 25g of protein.

Dietary Supplement: Bolus ingestion of protein
Ingestion of 25g of protein
Other Names:
  • Protein ingestion

    		•
    Experimental: Pea protein

    Bolus ingestion of pea protein providing 25g of protein.

    Dietary Supplement: Bolus ingestion of protein
    Ingestion of 25g of protein
    Other Names:
  • Protein ingestion

    		•
    Experimental: Mycoprotein/pea protein dry blend

    Bolus ingestion of mycoprotein/pea protein dry blend providing 25g of protein.

    Dietary Supplement: Bolus ingestion of protein
    Ingestion of 25g of protein
    Other Names:
  • Protein ingestion

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Muscle protein synthesis [8.5 hours]

      The rate of synthesis of new muscle protein (Fractional synthetic rate %/h)

    Secondary Outcome Measures

    1. Plasma amino acid kinetics [8.5 hours]

      The appearance of amino acids from the protein drink in the circulation.

    2. Serum insulin concentrations [8.5 hours]

      Basal and postprandial concentrations of serum insulin

    3. Translocation of mTOR via immunohistochemistry [8.5 hours]

      Locality of mTOR within the muscle cell

    4. mTOR phosphorylation via ATP kinase assay [8.5 hours]

      The amount of mTOR that has been activated in the muscle cell

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 40 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • BMI between 18 and 30

    • Resistance trained

    Exclusion Criteria:

    • Any metabolic impairment

    • Smoking

    • Use of over the counter pharmaceuticals (excluding oral contraceptives and contraceptive devices).

    • A personal family history of epilepsy, seizures or schizophrenia.

    • Allergic to Quorn/mycoprotein/edible fungi/environmental mould products.

    • Any motor disorder.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Exeter Exeter United Kingdom

    Sponsors and Collaborators

    • University of Exeter
    • Quorn

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Exeter
    ClinicalTrials.gov Identifier:
    NCT04894747
    Other Study ID Numbers:
    • 200325_B_04UOE
    First Posted:
    May 20, 2021
    Last Update Posted:
    Feb 1, 2022
    Last Verified:
    Jan 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Feb 1, 2022